Novel GLP-1 Receptor Agonist Designated Orphan Drug for Polymyositis – Monthly Prescribing Reference

Home » News » Drugs in the Pipeline

Novel GLP-1 Receptor Agonist Designated Orphan Drug for Polymyositis

PF1801 is a novel long-acting GLP-1 receptor agonist. Credit: Getty Images.

The Food and Drug Administration (FDA) has granted Orphan Drug designation to PF1801 for the treatment of polymyositis.

Polymyositis is a type of inflammatory myopathy characterized by chronic muscle inflammation and weakness. The exact cause of the disease is unknown. PF1801 is a novel long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. Study findings suggest that activation of GLP-1 receptor signaling may be beneficial in the treatment of atrophy-related muscular diseases.

In a press release, ImmunoForge stated: “This Orphan Drug Designation is of great significance in confirming the potential of PF1801 as a treatment for rare musculoskeletal diseases, and we hope that it will serve as a source of hope for patients suffering from rare diseases with the various new drugs we are developing.”

The FDA previously granted Orphan Drug designation to PF1801 for the treatment of Duchenne muscular dystrophy.


Continue Reading

References

  1. ImmunoForge Inc. receives US FDA ODD for treatment of polymyositis. News release. ImmunoForge Inc. Accessed September 27, 2021. https://www.prnewswire.com/news-releases/immunoforge-inc-receives-us-fda-odd-for-treatment-of-polymyositis-301384587.html
  2. Pipeline: PF1801. ImmunoForge Inc. Accessed September 27, 2021. https://www.immunoforge.com/m21.php?slide=1&#section2.

Want to read more?

Please login or register first to view this content.

if ( typeof googletag != ‘undefined’ ) {
googletag.cmd.push(function() {
window.hmAds.registerAd( ‘div-gpt-ad-leaderboard_bottom’ );
});
}

The Food and Drug Administration (FDA) has granted Orphan Drug designation to PF1801 for the treatment of polymyositis.
Polymyositis is a type of inflammatory myopathy characterized by chronic muscle inflammation and weakness. The exact cause of the disease is unknown. PF1801 is a novel long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. Study findings suggest that activation of GLP-1 receptor signaling may be beneficial in the treatment of atrophy-related muscular diseases.
In a press release, ImmunoForge stated: “This Orphan Drug Designation is of great significance in confirming the potential of PF1801 as a treatment for rare musculoskeletal diseases, and we hope that it will serve as a source of hope for patients suffering from rare diseases with the various new drugs we are developing.”
The FDA previously granted Orphan Drug designation to PF1801 for the treatment of Duchenne muscular dystrophy.

Please login or register first to view this content.

Copyright © 2021 Haymarket Media, Inc. All Rights Reserved
This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.
Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions.

source